3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Thyroid Neoplasms
13
Thyroid Carcinoma, Anaplastic
9
Colorectal Neoplasms
5
Thyroid Cancer, Papillary
4
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Multiple Myeloma
3
Melanoma
3
Glioma
3
Adenocarcinoma, Follicular
3
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Hematologic Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid cancer, follicular
1
Thyroid cancer, Hurthle cell
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Refractory Differentiated Thyroid Gland Carcinoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Nonseminomatous germ cell tumor
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Mouth Neoplasms
1
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
1
Lymphoproliferative Disorders
1
Interventions
Cisplatin
4
pembrolizumab
3
selpercatinib
2
pralsetinib
2
Pemetrexed
2
Paclitaxel
2
Fulvestrant
2
Carboplatin
2
trametinib
1
ribociclib
1
repotrectinib
1
patritumab
1
palbociclib
1
golotimod
1
exemestane
1
dabrafenib
1
cobimetinib
1
alectinib
1
abemaciclib
1
Vemurafenib
1
Taxes
1
Tamoxifen
1
STX-478
1
Radiotherapy, Intensity-Modulated
1
Nimorazole
1
Metformin
1
Letrozole
1
Imlunestrant
1
Gemcitabine
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
trametinib
×
Head & Neck
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled